BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, March 15, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
May 3, 2010
View Archived Issues
Novexel discloses novel antibacterial agents
Read More
Novel SAPK1/JNK1 inhibitors identified by U.S. researchers
Read More
Array BioPharma discloses novel receptor tyrosine kinase inhibitors
Read More
Janus kinase inhibitors for cancer therapy claimed by Rigel Pharmaceuticals
Read More
U.S. scientists identify novel viral and fungal inhibitors
Read More
IMPACT-DCM results encourage larger trials of cardiac repair cells in dilated cardiomyopathy
Read More
Polo-like kinase 1 inhibitors from Cyclacel active in xenograft cancer models
Read More
LigoCyte updates norovirus vaccine clinical development progress
Read More
Cleveland Biolabs describes novel curaxin radiosensitizers for cancer
Read More
Phase III study of Roche's taspoglutide in type 2 diabetes meets primary endpoint
Read More
Novavax reports results for seasonal influenza VLP vaccine candidate
Read More
Pepscan and Immunovo sign agreement for Pepscan's therapeutic vaccine portfolio
Read More
Mydicar meets primary endpoint in phase II advanced heart failure trial
Read More
BioTime to acquire ES Cell International for development of stem cell-based therapeutics
Read More
TxCell reports preliminary results from phase I/IIa trial of OvaSave in Crohn's disease
Read More
BioMarin plans phase III trial of GALNS in MPS IVA following phase I/II results
Read More
Phase III Trinity study results reported for olmesartan/amlodipine/HCTZ in hypertension
Read More
Artisan completes enrollment in phase IIb ART-123 study in sepsis patients
Read More
Dynavax receives clearance to start two phase III Heplisav trials
Read More
Pieris reports preclinical data for its c-Met Anticalin drug
Read More
Celtic Therapeutics acquires rights to Kiacta from BELLUS Health
Read More
EnzymeRx reports phase I results for pegsitacase
Read More
Provectus reports on end-of-phase II meeting with FDA for PV-10
Read More
BARDA exercises options on Cleveland BioLabs contract to develop CBLB-502
Read More
FDA approves Vimovo delayed-release tablets for arthritis patients
Read More
Palmitoylethanolamide enhances efficacy of topical ocular antihypertensive treatments
Read More
